OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Treatment Reviews is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis	221
MYC as a target for cancer treatment	220
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies	140
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality	127
Global challenges and policy solutions in breast cancer control	117
Microsatellite instability in Gastric Cancer: Between lights and shadows	112
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	110
Targeting FGFR inhibition in cholangiocarcinoma	109
Treatment landscape of metastatic pancreatic cancer	107
BAP1: Not just a BRCA1-associated protein	105
MEK inhibitor resistance mechanisms and recent developments in combination trials	101
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives	90
Targeting ARID1A mutations in cancer	86
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins	83
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management	82
NRAS mutant melanoma: Towards better therapies	75
Immunotherapy in non-small cell lung cancer harbouring driver mutations	66
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	64
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis	60
Roadmap to cure multiple myeloma	60
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	58
Treatment strategies for patients with diffuse large B-cell lymphoma	56
Targeting brain metastases in breast cancer	55
Targeting HER2 heterogeneity in breast cancer	54
Turning tumors from cold to inflamed to improve immunotherapy response	53

Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis	51
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis	48
Cabozantinib: An evolving therapy for hepatocellular carcinoma	47
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis	47
Liquid biopsy in lymphoma: Molecular methods and clinical applications	47
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials	47
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives	46
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond	45
A basic review on systemic treatment options in WHO grade II-III gliomas	45
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer	44
Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis	44
Neurological complications of cancer immunotherapy	42
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification	41
Precision medicine in breast cancer: From clinical trials to clinical practice	41
SELNET clinical practice guidelines for soft tissue sarcoma and GIST	39
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer	39
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone	39
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis	37
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives	37
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials	37
Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer	36
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities	36
Immunotherapy in cervix cancer	36
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus	35
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice	35
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?	35
The current clinical landscape of personalized cancer vaccines	35
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities	34
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials	34
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges	34
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)	33
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines	33
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	33
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future	31
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era	31
Accelerating drug development in breast cancer: New frontiers for ER inhibition	31
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors	30
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer	30
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?	30
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care	29
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer	29
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer	29
Recent advancements of antiangiogenic combination therapies in ovarian cancer	28
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours	28
The promise of bispecific antibodies: Clinical applications and challenges	28
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immorta	27
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review	27
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis	27
Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review	27
Clinical trial data of Anti–PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review	27

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations	27
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer	27
Comparing cancer and cardiovascular disease trends in 20 middle- or high-income countries 2000–19: A pointer to national trajectories towards achieving Sustainable Development goal target 3.4	26
Clinical development of IDH1 inhibitors for cancer therapy	26
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers	26
Newly diagnosed ovarian cancer: Which first-line treatment?	26
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias	25
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis	25
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas	25
Seroprevalence of SARS-CoV-2–specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data	25
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?	25
Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis	24
The use of immunotherapy in older patients with advanced non-small cell lung cancer	23
Prognostic factors in patients with oligometastatic breast cancer – A systematic review	23
Organoid models in gynaecological oncology research	23
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications	23
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	22
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment	22
Beyond HER2: Targeting the ErbB receptor family in breast cancer	22
Novel targets for immune-checkpoint inhibition in cancer	22
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)	21
Targeting NaPi2b in ovarian cancer	21
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?	21
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC	21
A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research	21
Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis	20
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon	20
Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis	20
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group	20
Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)	20
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts	19
Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?	19
Rethinking breast cancer follow-up based on individual risk and recurrence management	19
Checkpoint inhibitors in metastatic papillary renal cell carcinoma	19
Current management and future perspectives of penile cancer: An updated review	19
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis	19
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants	19
Toxicities following CAR-T therapy for hematological malignancies	19
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis – A review	19
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences	19
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines	19
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer	18
Diagnostics, therapeutics and RET inhibitor resistance for RET fusion–positive non-small cell lung cancers and future perspectives	18
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data	18
HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage	18
De-escalation of axillary irradiation for early breast cancer – Has the time come?	18
The evolving landscape of antibody-drug conjugates in gynecologic cancers	18